Cancer Genetics Inc

Cancer Genetics — Q1 2015 Earnings Presentation

12 slides from Cancer Genetics's earnings presentation, May 12, 2015

  1. Slide 1: Q1 2015 Earnings Call

    May 12, 2015 Q1 2015 Earnings Call

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potenti

  3. Slide 3: 1st Quarter 2015 Revenue Highlights

    1st Quarter 2015 Revenue Highlights 3 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call Q 1 2 0 1 2 Q 1 2 0 1 3 Q 1 2 0 1 4 Q 1 2 0 1 5 0 $4.4 $1.4 $1.2 $0.8 4-Year CAGR 53% $4.5M $2M 578% BIOPHARMA REVENUE GROWTH FROM Q1 2014 Q1 TOTAL REVENUE GREW FROM $1.4M TO 206% REVENUE GROWTH FROM Q

  4. Slide 4: Revenues By Category

    Revenues By Category 4 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call 76% 20% 4% Q1 2015 BIOPHARMA SERVICES CLINICAL SERVICES DISCOVERY SERVICES $10.2 Mn $4.4 Mn  Launched new NGS panels, including Focus::Myeloid™  Repositioning of Go-To Market Strategy to concentration on clinical s

  5. Slide 5: Q1 2015 Financial Highlights

    Q1 2015 Financial Highlights 5  First quarter 2015 revenues were $4.4 million, a 206% increase over first quarter 2014 revenues of $1.4 million, and 8+% sequential growth over $4.0 million in the fourth quarter of 2014  Revenue from Biopharma Services grew 578% year-over-year during the first quar

  6. Slide 6: Summary Statement of Operations

    Summary Statement of Operations 6 Income Statement Item ($ in Thousands) Q1 2013 Q1 2014 Q1 2015 Revenue $1,219 $1,430 $4,370 Gross Profit 149 140 1,229 Gross Margin (%) 12% 10% 28% Research & Development (R&D) 491 597 1,278 Sales & Marketing (S&M) 397 749 1,116 General & Administrative (G&A) 1,571

  7. Slide 7: Expected Future Biopharma Revenues

    Expected Future Biopharma Revenues 7 Approximate expected future revenues under signed contracts with biotechnology and pharma customers for testing and services to support currently planned clinical trials. Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call December 2013 December 2012 Dec

  8. Slide 8: Significant Progress in our Disease-Specific NGS Panel Pipeline

    Significant Progress in our Disease-Specific NGS Panel Pipeline 8 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call RESEARCH & DISCOVERY CLINICAL DEVELOPMENT COMMERCIAL DEVELOPMENT LAUNCH & MARKET ENTRY FOCUS::CLL™ FOCUS::MYELOID™ (IN COLLABORATION WITH ILLUMINA) FOCUS::LYMPHOID™ MULTIPLE

  9. Slide 9: Focus::CLL NGS Panel

    Focus::CLL™ NGS Panel 9 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call  Launched in Q4 2014  Unique targeted NGS panel with 7 biomarkers for diagnosis, prognosis and patient management  The only targeted NGS panel available for CLL/SLL  Selected for use in global clinical trial by

  10. Slide 10: Focus::Myeloid NGS Panel

    Focus::Myeloid™ NGS Panel 10 Cancer Genetics, Inc. | NASDAQ: CGIX | Q1 2015 Earnings Call  Launched in Q1 2015  Comprehensive NGS panel with 54 biomarkers that provides actionable information for improved diagnosis, prognosis, and risk stratification  Delivers faster results on biomarkers in curr

  11. Slide 11: Upcoming Milestones

    Upcoming Milestones 11  Increasing covered lives market access through additional payers & health care organizations  Additional international agreements for FHACT® distribution and co-marketing partnerships in key geographies  Launching multi-marker NGS panel for lymphoid malignancies  Multiple

  12. Slide 12: Thank You

    Thank You Cancer Genetics, Inc. www.cancergenetics.com CGI Headquarters Meadows Office Complex 201 Route 17 North, 2nd Floor Rutherford, NJ 07070 Phone: +1 201-528-9200 Fax: +1 201-528-9235 Research Triangle Park 133 Southcenter Court, Ste. 400 Morrisville, NC 27569 Phone: +1 919-465-0100 Fax: +1 91

Cancer Genetics — Q1 2015 Earnings Presentation on 6ix